Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor (developmental 
the BMCMC were alcian blue positive, safranin negative, and berberine sulfate negative; had a histamine content of 0.1)8 ± 0.02 pg per cell; and incorporated [35S~sulfate into chondroitin sulfates. After 4 wk in rrSCF'64, the BMCMC were predominantly safranin positive and berberine sulfate positive, had a histamine content of 2.23 ± 0.39 pg per cell, and synthesized 35S-labeled proteoglycans that included substantial amounts (41-70%) of [35S] heparin. These rmdings identify SCF as a single cytokine that can induce immature, IL-3-dependent mast cells to mature and to acquire multiple characteristics of CTMC. These findings also directly demonstrate that SCF can regulate the development of a cellular lineage expressing c-kit through effects on both proliferation and maturation.
Mast cell development is a complex process that results in the appearance of phenotypically distinct populations of mast cells in different anatomical sites (reviewed in ref. 1). Connective tissue-type mast cells (CTMC), such as those present in the skin and peritoneal cavity, represent a major mast cell population in the mouse (1) . Mouse CTMC exhibit cytoplasmic reactivity with safranin and with the fluorescent heparinbinding dye berberine [1] [2] [3] [4] . It has been demonstrated that BMCMC can mature and acquire multiple phenotypic characteristics of CTMC either in vivo (5) or when cocultured with 3T3 cells in vitro (6) . Neverthe- less, the signals that regulate the maturation of immature mast cells into CTMC are not fully understood.
Several lines ofevidence indicate that interactions between products of the W and SI loci on mouse chromosomes 5 and 10 importantly influence CTMC development. Mice homozygous for mutations at these loci exhibit several striking phenotypic abnormalities including a macrocytic anemia (7, 8) and a virtual absence of tissue mast cells (9, 10) . Both in vivo and in vitro studies indicate that W mutations produce defects intrinsic to the erythroid and mast cell lineages, while SI mutations impair the tissue microenvironment required for normal erythroid and mast cell development (reviewed in refs. [8] [9] [10] . For example, IL-3-dependent BMCMC of (WBB6)F1 +/+ mouse origin developed into CTMC when adoptively transferred to appropriate anatomical sites, such as the skin or peritoneal cavity, of genetically mast celldeficient (WBB6)F1 WIW' mice (5) . By contrast, normal BMCMC failed to survive or develop into CTMC in the skin of genetically mast cell-deficient (WCB6)F1 S1S1d mice (11) . In vitro studies showed that fibroblasts derived from normal or (WBB6)F1 WIWv mice supported the survival and proliferation of normal BMCMC in vitro, whereas fibroblasts derived from (WCB6)F1 S1S1d mice did not (reviewed in ref.
9). Moreover, mast cells developed on membranes that had been covered with (WCB6)F1 +/+ 3T3 fibroblasts, but not on membranes covered with (WCB6)F1 S1/S"d 3T3 fibroblasts, after introduction of these membranes into the peritoneal cavity of SIIS1d mice (9, 12) .
Products of the W or SI loci that influence mast cell development have recently been identified. The W locus encodes the c-kit tyrosine kinase receptor (13, 14) , whereas Sl encodes a c-kit ligand (15) (16) (17) (18) (19) (20) (21) (22) (23) , which we have designated stem cell factor (SCF) (18) (19) (20) 23) . Three groups demonstrated independently that recombinant SCF (18, 19) or other examples of this c-kit ligand (15, 21, 22, 24) can induce proliferation of certain populations of mouse mast cells in vitro, and we showed that subcutaneous injection of the recombinant rat factor, rrSCF'1, permits mast cells to develop in genetically mast cell-deficient (WCB6)F1 S1S1d mice in vivo (20) . However, it was not determined whether SCF could induce the development of dermal mast cells in normal mice. Nor was it known whether SCF influenced mast cell maturation as well as proliferation.
MATERIALS AND METHODS
Cells. Mouse mast cell populations were derived, maintained, or purified (peritoneal mast cells, PMC) as described in detail (2, 25, 26) . Briefly, PT-18 is an IL-3-dependent cell line derived from C3H.SW mouse spleen cells (26 (2, 25) . PMC were purified from the peritoneal cavities of retired breeder BALB/c mice (The Jackson Laboratory) as described (25) . Mast cells were counted after staining with neutral red (5) .
SCF. In vitro experiments were performed with rrSCF1M
purified from Escherichia coli as described in detail (19 Incorporation of [3H]thymidine over a 4-h period was then determined as described above. In each experiment, some wells contained cells in only complete medium (negative control) or IL-3-containing CM (as described above). To identify proliferating cells in these preparations, cells were permitted to incorporate 5-bromodeoxyuridine (3 ,ug/ml; Boehringer Mannheim) over a 30-min incubation period at 37°C, and then cytocentrifuge preparations were processed for colocalization of nuclear staining with a monoclonal antibody to 5-bromodeoxyuridine (Becton Dickinson), used according to the supplier's instructions, and mast cell cytoplasmic granules were stained with alcian blue (29) .
For assessment of effects of SCF on mast cell phenotype, BMCMC or purified PMC were maintained in complete medium supplemented with rrSCFlM (50 ng/ml, replaced two or three times weekly) for 2-6 wk. Some BMCMC were also maintained in IL-3-containing CM. For assessment of histochemical characteristics, mast cells were analyzed in cytocentrifuge preparations fixed in Carnoy's fixative for staining with berberine sulfate and in air-dried cytocentrifuge preparations stained with alcian blue and safranin (5) . Mast cell histamine content was measured by the fluorometric method of Shore (30 administration of rrSCF164 on mast cell populations was restricted to the vicinity of the injection site; no increase in mast cell numbers was seen in sections of other cutaneous sites or the stomach of these mice. And in +/+ mice, in contrast to S1/Sd mice (20) , injection of rrSCF11 had little or no effect on Hct (Table 1) . Administration of rrSCF11 to genetically mast cell-deficient (WBB6)F1 W/W' mice, at doses up to 100 ,uggkg-1 day-1 s.c. for 3 wk, failed to repair the dermal mast cell deficiency of these mutants (data not shown).
When representative sections from SCF injection sites were examined by histochemistry, we found that most of the mast cells exhibited cytoplasmic reactivity with berberine sulfate and that many, but not all, of the mast cells stained with safranin. The presence of increased numbers of mast cells positive for berberine sulfate or safranin in the skin of mice injected with SCF does not necessarily indicate that SCF promotes mast cell maturation, however; this finding may have reflected simply the SCF-induced proliferation of the population ofberberine sulfate-positive, safranin-positive CTMC that ordinarily resides in the dermis of normal mice. To assess separately the effects of rrSCF1M on the proliferation or maturation of mast cells, we therefore analyzed mast cell populations exposed to rrSCF11 in vitro. (Fig. 1) . rrSCF16 of the IL-3-dependent cloned mast ce IL-3-dependent BMCMC from either I or (WBB6)F1 +/+ mice (Fig. 1C) and which comprise an IL-3-independent CTMC mast cells (reviewed in ref. I derived from (WBB6)F1 WIW" mice proliferative response to rrSCFlM, v B significant (P = 0.014 vs. cells maintained without rrSCF164 by two-tailed Student's t test) only at a rrSCF164 concentration of 500 ng/ml (Fig. 1D ). This result is consistent with previous work indicating that the W and W" alleles encode c-kit receptors that express no (W) or markedly diminished (WV) tyrosine kinase activity (33) and indicates that the effects of rrSCF164 on mast cell proliferation require the interaction of the cytokine with a functional c-kit receptor. The cells in Fig. 1 that responded (Fig. 2b) or safranin (Fig. 2e) . We found that when BMCMC r cells incubated without were maintained in rrSCF'1 (50 ng/ml) for 4 wk ( (Fig. 1A) , sulfate by BMCMC maintained in rrSCF1" reflected an BALB/c mice (Fig. 1B) increased ability of these populations to synthesize heparin, I purified mouse PMC, we biochemically analyzed the 35S-labeled proteoglycans population of mature synthesized by BMCMC maintained in the presence or 1) (Fig. 1D) Fig. 1 for 4 or 8 wk or were maintained in CM for 4 wk and then transferred to medium lacking IL-3 but containing rrSCF1" (50 ng/ml) for an additional 4 wk. PMC were used immediately after purification or after 2 wk in medium containing rrSCF16 (50 ng/ml). Medium containing rrSCF161 was replaced two or three times per wk. Mast cells in cytocentrifuge preparations were stained for alcian blue/safranin or berberine sulfate; at least 100 cells were examined in each preparation. AB+/S-, all granules AB+, no granules S+; AB+ > S+, more AB' than S+ granules; S+ > AB', more SI than AB+ granules. Berberine sulfate: -, no berberine sulfate positive granules; ±, occasional weakly positive granules; +, many positive granules; + +, many intensely positive granules. Histamine content was determined by a fluorometric method. Data shown are means ± SEM (n = 3-8 per point). rrSCF11 also induced phenotypic changes in PMC. Nocka et al. (24) reported that a c-kit ligand (21) purified from CM of BALB/3T3 fibroblasts stimulated the proliferation of PMC in vitro and that the cytoplasmic granules of these cells stained with berberine sulfate. We also found that many PMC maintained in vitro with rrSCF1" retained reactivity with berberine sulfate (Table 2) . However, our results indicate that some PMC maintained in rrSCF1M had no detectable cytoplasmic staining with berberine sulfate or exhibited diminished reactivity with safranin (Table 2 ). In addition, PMC maintained in rrSCF11 had a histamine content very similar to that of BMCMC maintained in rrSCFlM but only ==12% that of freshly isolated PMC ( phenotypic characteristics that are different than those typical of the resting populations (reviewed in refs. 1 and 35) .
The mechanisms by which SCF influences mast cell proliferation and maturation remain to be fully elucidated. Our experiment with (WBB6)F1 WIW" BMCMC confirms a previous report (24) indicating that the effects of SCF on mast cell proliferation in vitro require that the c-kit ligand interacts with a functionally competent c-kit receptor. However, the subsequent events leading to mast cell proliferation and/or maturation are not known. By itself, SCF has relatively modest effects on the proliferation of hematopoietic or lymphoid cells in vitro, but it acts in potent synergy with other cytokines to influence the development of specific erythroid, myeloid, or lymphoid lineages (18) (19) (20) 22) . We have obtained preliminary evidence that rrSCF164 can activate certain mouse mast cell populations to release their mediators (37) . Although the concentrations of rrSCFlM required to observe these effects in vitro are substantially higher than those required to induce proliferation of the same cells, activation of dermal mast cells in vivo is observed at rrSCF164 doses even lower than those we used to induce expansion of this population. Activation of mast cells generated in vitro, either via the FceRI or by other mechanisms, induces these cells to develop increased levels of mRNA for several cytokines and/or to secrete the products (25, (38) (39) (40) . Some of these cytokines-e.g., IL-3 and IL-4-can promote or augment mast cell proliferation (reviewed in refs. [38] [39] [40] [41] [42] . In light of these findings, it will be of interest to determine whether one of the actions of SCF is to induce mast cells to generate other cytokines with autocrine effects on mast cell proliferation and/or maturation.
